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Abstract
The human cytomegalovirus (hCMV) major immediate-early 1 protein (IE1) is best known
for activating transcription to facilitate viral replication. Here we present transcriptome data
indicating that IE1 is as significant a repressor as it is an activator of host gene expression.
Human cells induced to express IE1 exhibit global repression of IL6- and oncostatin M-
responsive STAT3 target genes. This repression is followed by STAT1 phosphorylation and
activation of STAT1 target genes normally induced by IFNγ. The observed repression and
subsequent activation are both mediated through the same region (amino acids 410 to 445)
in the C-terminal domain of IE1, and this region serves as a binding site for STAT3. Deple-
tion of STAT3 phenocopies the STAT1-dependent IFNγ-like response to IE1. In contrast,
depletion of the IL6 receptor (IL6ST) or the STAT kinase JAK1 prevents this response.
Accordingly, treatment with IL6 leads to prolonged STAT1 instead of STAT3 activation in
wild-type IE1 expressing cells, but not in cells expressing a mutant protein (IE1dl410-420)
deficient for STAT3 binding. A very similar STAT1-directed response to IL6 is also present
in cells infected with a wild-type or revertant hCMV, but not an IE1dl410-420 mutant virus,
and this response results in restricted viral replication. We conclude that IE1 is sufficient
and necessary to rewire upstream IL6-type to downstream IFNγ-like signaling, two path-
ways linked to opposing actions, resulting in repressed STAT3- and activated STAT1-
responsive genes. These findings relate transcriptional repressor and activator functions of
IE1 and suggest unexpected outcomes relevant to viral pathogenesis in response to
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cytokines or growth factors that signal through the IL6ST-JAK1-STAT3 axis in hCMV-
infected cells. Our results also reveal that IE1, a protein considered to be a key activator of
the hCMV productive cycle, has an unanticipated role in tempering viral replication.
Author Summary
Our previous work has shown that the human cytomegalovirus (hCMV) major immedi-
ate-early 1 protein (IE1) modulates host cell signaling pathways involving proteins of the
signal transducer and activator of transcription (STAT) family. IE1 has also long been
known to facilitate viral replication by activating transcription. In this report we demon-
strate that IE1 is as significant a repressor as it is an activator of host gene expression.
Many genes repressed by IE1 are normally induced via STAT3 signaling triggered by inter-
leukin 6 (IL6) or related cytokines, whereas many genes activated by IE1 are normally
induced via STAT1 signaling triggered by interferon gamma (IFNγ). Our results suggest
that the repression of STAT3- and the activation of STAT1-responsive genes by IE1 are
coupled. By targeting STAT3, IE1 rewires upstream STAT3 to downstream STAT1 signal-
ing. Consequently, genes normally induced by IL6 are repressed while genes normally
induced by IFNγ become responsive to IL6 in the presence of IE1. We also demonstrate
that, by switching an IL6 to an IFNγ-like response, IE1 tempers viral replication. These
results suggest an unanticipated dual role for IE1 in either promoting or limiting hCMV
propagation and demonstrate how a key viral regulatory protein merges two central cellu-
lar signaling pathways to divert cytokine responses relevant to hCMV pathogenesis.
Introduction
Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathways
are the principal means by which responses to dozens of cytokines, growth factors and other
extracellular molecules are transduced from the cell surface to the nucleus. Although all JAK--
STAT pathways share the same design principle, they involve distinct sets of ligands that
engage different receptor and effector components to activate groups of genes which only
partly overlap [1, 2].
For interleukin (IL) 6 family cytokines, including IL6 and oncostatin M (OSM), JAK-STAT
pathway activation begins with ligand binding to specific receptors, such as the IL6 receptor
(IL6Rα or IL6R) and the OSM receptor, respectively. The ligand-receptor interaction is fol-
lowed by dimerization of the IL6 signal transducer (IL6Rβ, GP130 or IL6ST) subunits common
to all IL6 family cytokine receptors. IL6ST is constitutively associated with several JAK family
tyrosine kinases (JAK1, JAK2 and TYK2) of which JAK1 seems to be the most important for
signaling in response to IL6 [3, 4]. Upon receptor activation, JAK1 is phosphorylated and the
activated kinase subsequently phosphorylates tyrosine residues in the cytoplasmic tail of
IL6ST. These phosphotyrosines serve as docking sites for the src homology 2 (SH2) domain of
cytoplasmic STAT3. Following recruitment to the receptor, STAT3 is phosphorylated on a sin-
gle tyrosine residue (Y705) by JAK1 or other kinases. Y705 phosphorylation is required for the
formation of functional STAT3 dimers (typically homodimers) through reciprocal SH2-pho-
sphotyrosyl interactions. The active pSTAT3 dimers subsequently dissociate from the receptor
and accumulate in the nucleus, most likely coordinate with their ability to bind DNA [5]. DNA
binding occurs rather sequence-specifically, resulting in transcriptional activation of select
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target genes involved in diverse processes including cell survival and proliferation [1, 6, 7]. One
of the pSTAT3 target genes encodes the suppressor of cytokine signaling 3 (SOCS3) which
forms part of a negative feedback circuit by inhibiting IL6 signaling [8, 9].
Another group of cytokines, the interferons (IFNs), are distinct from the IL6-type cytokines
but also trigger signaling through JAK-STAT pathways. For type I IFNs, including IFNα and
IFNβ, canonical signaling occurs through the IFNα/β receptor subunits (IFNAR1 and
IFNAR2), JAK1 and TYK2, and a trimeric complex of tyrosine-phosphorylated STAT1 and
STAT2 with IFN regulatory factor 9 (IRF9). This complex is also referred to as IFN-stimulated
gene factor 3 (ISGF3) and activates transcription of numerous genes many of which encode
anti-viral products [10, 11]. For IFNγ, the only type II IFN, signaling is typically mediated via
the IFNγ receptor (IFNGR) subunits 1 and 2, JAK1 and JAK2, and tyrosine (Y701)-phosphory-
lated STAT1 (pSTAT1) homodimers. Like other STAT proteins, STAT1 also undergoes serine
(S727) phosphorylation adding to its potency as a transcriptional activator. By triggering pro-
longed STAT1 activation, type II IFN signaling results in the induction of numerous genes
broadly defined as immune-modulatory [12, 13].
The pathways responsive to IL6-type cytokines or IFNγ share important intracellular signal-
ing molecules, but have been linked to opposing actions. STAT3 generally promotes cell sur-
vival and proliferation, may counteract inflammation and induces immune tolerance. In
contrast, STAT1 tends to promote apoptosis, inhibits proliferation and favors innate or adap-
tive immune responses. Due to cross-regulation between the two pathways, perturbations in
the levels or activities of STAT1 and STAT3 may redirect cytokine signals with unexpected out-
comes [14–17].
Many viruses target components of JAK-STAT pathways including STAT1, STAT2 and
STAT3. STAT1 and STAT2 usually act anti-viral due to their essential roles in IFN signaling
[10, 12]. Accordingly, most viruses antagonize STAT1 or STAT2 [18, 19], although viral activa-
tion and annexation of STAT1 has also been reported [20–28]. For STAT3, the role in viral
infections appears to be more complex. Thus, viruses either positively or negatively affect the
expression or activity of STAT3 [29–36].
Human cytomegalovirus (hCMV), one of eight human herpesviruses, is a very widespread
opportunistic pathogen. To accomplish efficient replication and lasting persistence, hCMV
seems to tweak most, if not all, host cell signaling pathways [37–40]. The 72-kDa (491 amino-
acid) immediate-early 1 protein (IE1) has emerged as hCMV’s key modulator of JAK-STAT
signaling [41–46]. Following infection of permissive cells, IE1 is among the very first and most
abundant gene products produced de novo from the hCMV genome. The viral protein accumu-
lates in the host cell nucleus and sets the stage for efficient hCMV early gene expression and
subsequent viral replication [47–51]. The first hint suggesting IE1 may impact JAK-STAT
pathways came from our finding that the protein confers increased type I IFN resistance to
hCMV without negatively affecting IFN expression [52]. This phenotype was partly attributed
to nuclear complex formation between IE1 and STAT2 depending on amino acids 373 to 445
[53] or 421 to 475 [54] in the viral protein’s C-terminal domain (amino acids 373 to 491). This
domain is thought to be structurally largely disordered and contains four patches with highly
biased amino acid composition: three acidic ‘domains’ (AD1-AD3) and one serine/proline-rich
stretch (S/P) [41, 53, 55]. The sequences downstream from the STAT2 interaction site in the C-
terminal domain of IE1 feature a small ubiquitin-like modifier (SUMO) conjugation motif
(amino acids 449–452) [56–58] and a chromatin tethering domain (CTD, amino acids 476–
491) [59–61] which mediate binding to SUMO1 and to the acidic pocket formed by histones
H2A-H2B on the nucleosome surface [62], respectively. SUMOylation of IE1 may negatively
regulate STAT2 binding [54] and positively affect hCMV replication [58]. IE1-STAT2 interac-
tion causes diminished sequence-specific DNA binding by ISGF3 and inhibited type I ISG
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activation in the presence of IFNα or IFNβ [52–54, 63]. The viral protein’s ability to inhibit
type I ISG induction via STAT2 interaction is believed to be important, because it contributes
to efficient hCMV replication [53, 54] and appears to be conserved across IE1 homologs of the
β-herpesvirus subfamily [64]. Besides functioning as an antagonist of type I IFN signaling, IE1
can also act as an agonist of type II IFN signaling. Following expression under conditions mim-
icking the situation during hCMV infection, IE1 elicited a host transcriptional response domi-
nated by the up-regulation of genes normally induced by IFNγ. The IE1-dependent gene
activation proved to be independent of IFNγ and other IFNs, yet required the Y701-phosphor-
ylated form of STAT1. Accordingly, IE1 induced Y701 and S727 phosphorylation, nuclear
accumulation and binding of STAT1 to type II ISG promoters [21]. Whether IE1 binds to
STAT1 directly or only indirectly (via STAT heterodimers) has not been resolved. Finally,
STAT3 was shown to physically interact with IE1, most likely via direct binding. The functional
consequences of this interaction include STAT3 nuclear accumulation, disruption of IL6-in-
duced STAT3 Y705 phosphorylation and inhibition of STAT3 binding to the SOCS3 promoter.
These events are followed by diminished STAT3-dependent SOCS3 induction upon hCMV
infection or IE1 expression [30] adding to the emerging evidence for transcriptional repression
by the viral protein. However, IE1 has mostly been recognized as an activator of cellular and
viral gene expression [42, 65] and, to the best of our knowledge, no genome-wide analysis of
human genes repressed by the viral protein has been pursued.
Here we show, based on genome-wide transcriptome data, that IE1 is as much a repressor as it
is an activator of human gene expression. We further demonstrate that a single motif (amino acids
410 to 420) in the C-terminal domain of IE1 links the viral protein’s repressor and activator func-
tions by rewiring upstream IL6-type to downstream IFNγ-like signaling resulting in repressed
STAT3- and activated STAT1-responsive genes. Finally, the diversion of STAT3/STAT1 signaling
attenuates viral replication revealing an unanticipated temperance activity in IE1.
Results
IE1 is as significant a repressor as it is an activator of host gene
expression
We previously reported on an Affymetrix GeneChip analysis of human transcripts undergoing
up-regulation in MRC-5 cells transduced to express doxycycline (dox)-inducible IE1 (TetR-IE1
cells). Expression from the preponderant majority (>98%) of genes represented on the Gene-
Chips was not significantly affected by IE1. However, a set of genes were specifically and repro-
ducibly up-regulated by the viral protein [21]. Upon further inspection of the GeneChip data,
we noticed that the IE1-dependent changes in the human transcriptome were not biased
towards activation. Instead, the numbers of genes significantly up- or down-regulated by IE1
were roughly the same (410 up-regulated and 436 down-regulated probe sets). Notably, at 24 h
post IE1 induction there were fewer (<42%) up-regulated compared to down-regulated genes,
whereas after 72 h of IE1 expression the up-regulated (>52%) slightly outbalanced the down-
regulated genes (Fig 1 and S1 Data).
These data indicate that IE1 is not only an activator, but also a significant repressor of host
gene transcription.
IE1 down-regulates IL6- and OSM-responsive pSTAT3 target genes
Our previous study has shown that the genes activated by IE1 in the TetR-IE1 cell model are
largely responsive to pSTAT1 and IFNγ [21]. To identify upstream regulators common to
genes repressed by IE1, we used Ingenuity Pathway Analysis. Among probe sets exhibiting
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negative fold changes of1.5, this analysis identified highly significant associations with
STAT3 (p-value of overlap with reference set = 2.5×10−13), OSM (p = 6.2×10−9), IL6
(p = 1.2×10−7) and other components of STAT3-dependent signaling pathways including cyto-
kines (e.g., leukemia inhibitory factor [LIF], p = 8.2×10−8, and granulocyte colony-stimulating
factor [GCSF], p = 8.4×10−7), growth factors (e.g., hepatocyte growth factor, p = 2.2×10−5, and
epidermal growth factor, p = 2.6×10−4) and receptors (e.g., IL10 receptor α, p = 1.2×10−6, and
IL6ST, p = 1.2×10−4). Consistently, 50 genes known to be positively regulated by STAT3, IL6
or/and OSM were identified among the IE1-repressed genes based on Ingenuity Pathway Anal-
ysis (Table 1). Moreover, the majority of genes most significantly repressed by IE1 are known
STAT3 targets (Table 2).
Out of the genes identified to be repressed by IE1, we selected six (C4A, CHL1, CXCL12,
IFI16, RASL11A and SOCS3) for validation by reverse transcriptase quantitative PCR (RT-
qPCR). The genes were selected to reflect the full range of repression magnitudes and kinetics
measured by GeneChip analysis. The RT-qPCR approach confirmed IE1-dependent down-reg-
ulation of all tested genes (Fig 2A). Many genes identified to be repressed by IE1, such as
CXCL12, IFI16 and SOCS3, are known targets of STAT3 or its upstream activators including
IL6 and OSM (Tables 1 and 2). However, to our knowledge, C4A, CHL1 and RASL11A have
not been previously linked to activation by STAT3, IL6 or OSM. We therefore examined the
effects of IL6 and OSM treatment on the mRNA levels of our select set of IE1-repressed genes.
Since fibroblasts do not express sufficient levels of the IL6 receptor α subunit (IL6R) to mount
a robust response, IL6 was used in combination with a soluble form of IL6R. The results dem-
onstrate that all tested genes are activated by both IL6 and OSM, although to varying degrees
(Fig 2B and 2C). To investigate whether these genes are also STAT3-responsive, STAT3 was
Fig 1. IE1 is both an activator and a repressor of human gene expression.Relative proportions and
absolute counts (in brackets) of unique probe sets significantly up- or down-regulated in GeneChip analyses
following induction of IE1 for 24 h, 72 h or 24 h and 72 h combined (total). The numbers are based on S1
Data.
doi:10.1371/journal.ppat.1005748.g001
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silenced with two different siRNA duplexes. Both siRNAs were equally efficient in knocking-
down STAT3 expression as confirmed by immunoblotting (Fig 2D, left panel). Following
depletion of STAT3 with either of the two siRNAs, all six tested genes exhibited reduced levels
of expression (Fig 2D, right panel). Likewise, STAT3 knock-down using two different dox-
inducible shRNA constructs demonstrated STAT3-responsive expression for 12 out of 14
Table 1. Ingenuity analysis1 of human genes repressed by IE1 and activated by STAT3, IL6 or OSM.
STAT32 IL63 OSM4
Probe5 Gene6 Change7 Ref.8 Probe5 Gene6 Change7 Ref.8 Probe5 Gene6 Change7 Ref.8
8092169 TNFSF10 -3.1 [81] 8018864 SOCS3 -3.0 [125] 8018864 SOCS3 -3.0 [126]
8018864 SOCS3 -3.0 [127] 8062461 LBP -2.9 [128] 8062461 LBP -2.9 [97]
8062461 LBP -2.9 [129] 8100393 KDR -2.7 [130] 7898057 PDPN -2.5 [12]
8100393 KDR -2.7 [131] 8095744 AREG -2.4 [132] 7933194 CXCL12 -2.2 [133]
7923547 CHI3L1 -2.5 [134] 7902527 PTGFR -2.1 [135] 7903920 CHI3L2 -2.1 [136]
8095744 AREG -2.4 [132] 8043995 IL1R1 -2.1 [137] 8097991 TDO2 -2.1 [138]
7933194 CXCL12 -2.2 [81] 8114612 CD14 -2.1 [139] 8008454 ABCC3 -2.0 [140]
8141016 TFPI2 -2.2 [133] 8008454 ABCC3 -2.0 [140] 8069689 ADAMTS5 -2.0 [141]
7903393 S1PR1 -2.1 [142] 8069689 ADAMTS5 -2.0 [143] 8091411 TM4SF1 -2.0 [136]
7937335 IFITM1 -2.1 [81] 8092691 BCL6 -2.0 [144] 8069676 ADAMTS1 -1.9 [141]
8043995 IL1R1 -2.1 [145] 8004510 CD68 -1.9 [146] 8105040 OSMR -1.9 [147]
7971015 SMAD9 -2.0 [82] 8069676 ADAMTS1 -1.9 [148] 8151447 IL7 -1.9 [149]
8092691 BCL6 -2.0 [150] 8136557 TBXAS1 -1.9 [151] 8122365 ADGRG6 -1.8 [12]
8151447 IL7 -1.9 [152] 8149927 CLU -1.9 [153] 7933084 NAMPT -1.6 [154]
7906400 IFI16 -1.8 [155] 8151447 IL7 -1.9 [156] 8015607 STAT3 -1.6 [157]
7924987 AGT -1.8 [158] 7906400 IFI16 -1.8 [158] 8123598 SERPINB1 -1.6 [136]
8055952 NR4A2 -1.8 [159] 7924987 AGT -1.8 [160] 8140556 HGF -1.6 [133]
7905789 IL6R -1.7 [161] 8152522 ENPP2 -1.8 [162] 8156199 DAPK1 -1.6 [136]
7945371 IFITM3 -1.7 [163] 7905789 IL6R -1.7 [164] 7926875 BAMBI -1.5 [136]
8130556 SOD2 -1.7 [165] 7945371 IFITM3 -1.7 [160] 8061564 ID1 -1.5 [166]
8174598 IL13RA2 -1.7 [132] 8130556 SOD2 -1.7 [167] 8150592 CEBPD -1.5 [97]
7933084 NAMPT -1.6 [154] 7933084 NAMPT -1.6 [154] 8169580 IL13RA1 -1.5 [136]
7937330 IFITM2 -1.6 [168] 8015607 STAT3 -1.6 [157]
8015607 STAT3 -1.6 [169] 8140556 HGF -1.6 [170]
8065071 FLRT3 -1.6 [81] 7897877 TNFRSF1B -1.5 [171]
8123598 SERPINB1 -1.6 [81] 7905047 FCGR1A -1.5 [172]
8140556 HGF -1.6 [173] 8061564 ID1 -1.5 [174]
7897877 TNFRSF1B -1.5 [175] 8119161 PIM1 -1.5 [176]
7905047 FCGR1A -1.5 [177] 8150592 CEBPD -1.5 [97]
8119161 PIM1 -1.5 [178]
8150592 CEBPD -1.5 [179]
1 Ingenuity Pathway Analysis (Core Analysis, default analysis settings) of all down-regulated probe sets from S1 Data.
2 STAT3 target genes identiﬁed by Ingenuity Upstream Analysis.
3 IL6 target genes identiﬁed by Ingenuity Upstream Analysis.
4 OSM target genes identiﬁed by Ingenuity Upstream Analysis.
5 Affymetrix Probe Set ID.
6 Gene Symbol (National Center for Biotechnology Information); genes further pursued in this work are bold-typed.
7 Maximum average fold change in comparisons of dox-treated TetR-IE1 vs. dox-treated TetR or dox-treated TetR-IE1 vs. solvent-treated TetR-IE1 cells 24
h or 72 h post induction.
8 Key reference.
doi:10.1371/journal.ppat.1005748.t001
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tested genes (S1 Fig). Finally, we tested the effects of a mutant STAT3 protein (STA-
T3α_Y705F), which is expressed to similar levels as the wild-type protein and resistant to Y705
but not S727 phosphorylation (Fig 2E, left panel). This mutant protein is known to act in a
trans-dominant negative fashion on expression of STAT3-responsive genes [66]. Accordingly,
overexpression of STAT3α_Y705F resulted in reduced levels of all tested genes repressed by
IE1 (Fig 2E, right panel).
Table 2. Human genesmost significantly repressed by IE11.
Probe Set ID Gene Symbol 24 h post induction2 72 h post induction3 STAT3-responsive4
IE1+/TetR+ IE1+/IE1- IE1+/TetR+ IE1+/IE1-
8077270 CHL1 -2.8 -1.5 -5.5 -2.8 Fig 2
8005048 MYOCD -3.9 -1.7 -4.2 -1.9 S1 Fig
8141094 PDK4 -3.8 -1.3 -3.5 -1.4 S1 Fig
8156706 TMOD1 -1.9 -1.5 -3.3 -2.6 S1 Fig
7929511 ENTPD1 -2.5 -1.2 -3.1 -1.5 [180]
8018864 SOCS3 -2.8 -2.1 -3.0 -2.5 Fig 2
8095585 SLC4A4 -1.7 -1.2 -3.0 -2.1 [180]
8077366 LRRN1 -2.1 1.1 -3.0 -1.1 S1 Fig
8062461 LBP -2.1 -1.2 -2.9 -1.5 [180]
7925929 AKR1C3 -2.4 -1.6 -2.8 -2.2 S1 Fig
7921916 RGS5 -2.8 -1.1 -2.8 1.0 S1 Fig
8178712 TNXB -1.6 -1.2 -2.7 -2.0 [82]
8179935 TNXB -1.6 -1.2 -2.7 -2.0 [82]
8092169 TNFSF10 -3.1 -1.2 -2.7 1.0 [81]
8149825 STC1 -2.0 1.0 -2.7 -1.5 —5
8166632 GK -2.4 -1.7 -2.6 -1.7 [81]
8101788 UNC5C -2.4 -1.1 -2.6 -1.4 [180]
8174103 GK -2.4 -1.7 -2.5 -1.7 [81]
7923547 CHI3L1 -1.1 -1.2 -2.5 -2.4 [134]
7898057 PDPN -2.2 1.0 -2.5 -1.1 [180]
7968236 RASL11A -2.1 -1.6 -2.4 -2.2 Fig 2
8100109 GABRA2 -2.6 -1.2 -2.4 -1.1 [180]
8118409 C4A -1.4 -1.2 -2.4 -2.2 Fig 2
8118455 C4A -1.4 -1.2 -2.4 -2.2 Fig 2
8179399 C4A -1.4 -1.2 -2.4 -2.2 Fig 2
7972157 EDNRB -3.3 -1.2 -2.4 1.0 S1 Fig
8063437 TSHZ2 -2.5 -1.3 -2.3 -1.3 [180]
8057486 PDE1A -1.3 -1.3 -2.3 -2.3 S1 Fig
7918857 TSPAN2 -3.2 1.0 -2.3 1.5 S1 Fig
8056376 SCN3A -1.2 -1.6 -2.2 -2.7 [180]
8063444 TSHZ2 -2.6 -1.3 -2.2 -1.2 [180]
8064868 GPCPD1 -2.7 -1.1 -2.2 -1.2 S1 Fig
8045539 KYNU -2.6 -1.2 -2.2 -1.1 [81]
7933194 CXCL12 -1.2 -1.2 -2.2 -2.2 Fig 2
7908376 RGS18 -3.6 -1.3 -2.2 1.0 S1 Fig
7902527 PTGFR -1.7 -1.6 -2.1 -2.1 —5,6
8166925 MAOA -2.8 -1.2 -2.1 1.0 [180]
8151942 HRSP12 -1.3 -1.3 -2.0 -2.0 S1 Fig
7985032 (LOC391532)7 -2.2 -2.6 1.4 -1.2 ND
(Continued)
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These findings support the conclusion that most genes found to be down-regulated by IE1
in our system are IL6- and OSM-responsive pSTAT3 target genes, including genes not previ-
ously linked to this pathway.
Physical and functional interaction with STAT3 maps to amino acids 410
to 445 in IE1
Next, we set out to map the physical determinants of STAT3-directed repression in IE1 and to
relate them to other known activities of the viral protein. Previous work by us and Huh et al.
has narrowed down STAT2 interaction to a region between amino acids 373 and 445 or 421
and 475, respectively, in the C-terminal quarter of IE1 [53, 54] suggesting that STAT3 might
also bind to this part of the viral protein. The four low complexity stretches (AD1, S/P, AD2
and AD3), the sequences (including the SUMOylation motif) linking these stretches and the
CTD were individually deleted resulting in a set of eight mutant proteins spanning the entire
IE1 C-terminal region between amino acids 373 and 491 (Fig 3A). Subsequently, MRC-5 cells
were transduced with lentiviruses expressing the wild-type or mutant IE1 proteins to generate
a correspondent set of dox-inducible cell lines. Following induction, the steady-state IE1 levels
in each mutant cell line were comparable to those of TetR-IE1 cells expressing the full-length
viral protein (Fig 3B). The IE1 mutants lacking an intact VKSE motif (IE1dl446-450 and
dl451-475) failed to undergo SUMOylation, as expected. IE1dl476-491 was not SUMOylated
either, suggesting that the CTD is required in addition to the VKSE motif for this posttransla-
tional modification (Fig 3C).
All mutant proteins displayed nuclear localization undistinguishable from wild-type IE1, as
determined by immunofluorescence microscopy (Fig 4A). When testing for nuclear accumula-
tion of STAT3, cells expressing IE1dl373-386, dl387-394, dl395-409, dl446-450, dl451-475 or
dl476-491 closely resembled wild-type expressing TetR-IE1 cells in exhibiting predominantly
nuclear diffuse STAT3 staining (>60% of cells) or, less frequently, a balanced distribution of
STAT3 between the nucleus and cytoplasm (<40% of cells). By contrast, in most cells express-
ing IE1dl410-420, dl421-445 or no IE1, STAT3 was either evenly distributed across the nucleus
and cytoplasm (>60% of cells) or predominantly present in the cytoplasm (<40% of cells), but
rarely if at all enriched in the nucleus (Fig 4A and 4B). The immunofluorescence results were
independently confirmed by subcellular fractionation analysis showing reduced STAT3 (but
Table 2. (Continued)
Probe Set ID Gene Symbol 24 h post induction2 72 h post induction3 STAT3-responsive4
IE1+/TetR+ IE1+/IE1- IE1+/TetR+ IE1+/IE1-
7906400 IFI16 -1.3 -1.4 -1.7 -1.8 Fig 2
12.0-fold average decrease in at least one or1.5-fold average decrease in at least two of the following four comparisons: dox-treated TetR-IE1
(TetR-IE1+) vs. dox-treated TetR (TetR+) cells 24 h post induction, TetR-IE1+ vs. TetR+ cells 72 h post induction, TetR-IE1+ vs. solvent-treated TetR-IE1
(TetR-IE1-) cells 24 h post induction or TetR-IE1+ vs. TetR-IE1- cells 72 h post induction; and1.5-fold average decrease in comparisons of TetR+ vs. TetR
cells 24 h or 72 h post induction. Symbols of genes further investigated in this work are bold-typed. IFI16 was further investigated despite narrowly missing
the criteria outlined above.
2 maximum average fold change in comparisons of TetR-IE1+ vs. TetR+ or TetR-IE1+ vs. TetR-IE1- cells 24 h post induction.
3 maximum average fold change in comparisons of TetR-IE1+ vs. TetR+ or TetR-IE1+ vs. TetR-IE1- cells 72 h post induction.
4 known target of STAT3 up-regulation or/and binding based on provided reference or this work (Fig 2, S1 Fig); ND, not determined.
5 not signiﬁcantly STAT3-responsive according to S1 Fig.
6 IL6-responsive according to Table 1.
7 long non-coding RNA.
doi:10.1371/journal.ppat.1005748.t002
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Fig 2. Human genes repressed by IE1 are IL6- and OSM-responsive pSTAT3 target genes. (A) TetR (w/o) and TetR-IE1 (IE1) cells were
treated with dox for 72 h. Relative mRNA levels were determined by RT-qPCRwith primers specific for the C4A, CHL1, CXCL12, IFI16,
RASL11A or SOCS3 genes. Results were normalized to TUBB, and means and standard deviations of biological triplicates are shown in
comparison to TetR cells (set to 1). (B) TetR cells were treated with solvent or IL6 plus IL6R (IL6/Rα) for 6 h or 24 h. Relative mRNA levels in
comparison to solvent-treated cells (set to 1) were determined by RT-qPCRwith primers specific for the indicated genes. Results were
normalized to TUBB, and means and standard deviations of biological triplicates are shown. (C) TetR cells were treated with solvent or OSM
for 24 h. Relative mRNA levels in comparison to solvent-treated cells (set to 1) were determined by RT-qPCR with primers specific for the
indicated genes. Results were normalized to TUBB, and means and standard deviations of biological triplicates are shown. (D) TetR cells were
transfected with the indicated siRNA duplexes. Two and five days post transfection (p.t.), whole cell protein extracts were prepared and
subjected to immunoblotting for STAT3α and GAPDH (left panel). Five days post transfection, relative mRNA levels were determined by RT-
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not STAT2) nuclear accumulation in cells expressing IE1dl410-420 or no IE1 compared to
wild-type IE1 expressing or IL6-treated cells (Fig 4C). In agreement with the subcellular locali-
zation analyses, IE1 amino acids 405 to 491 were sufficient (S2 Fig) and amino acids 410 to 420
were required (Fig 4D) for physical interaction with STAT3 when mutants were compared to
the full-length viral protein in co-immunoprecipitation assays (Fig 4D). Unlike wild-type IE1,
the mutant protein also proved to be unable to interfere with STAT3 binding to SOCS3 pro-
moter sequences, as analyzed by chromatin immunoprecipitation (ChIP) assay (Fig 4E).
Finally, repressed expression of the STAT3-responsive CXCL12 and SOCS3 genes was
observed with the wild-type and all tested mutant proteins except for IE1dl410-420 and dl421-
445 (Fig 4F).
qPCR with primers specific for the indicated genes. Results were normalized to TUBB, and means and standard deviations of two biological
and two technical replicates are shown in comparison to control siRNA-transfected cells (set to 1) (right panel). (E) Whole cell protein extracts
from TetR cells without (w/o) or with stable expression of the indicated STAT3α-Myc proteins were subjected to immunoblotting for STAT3
(Myc tag), TUBA, pSTAT3 (Y705) and pSTAT3 (S727) (left panel). Total RNA samples from TetR cells overexpressing either wild-type
STAT3α-Myc or STAT3α_Y705F-Myc were subjected to RT-qPCRwith primers specific for the indicated genes. Results were normalized to
TUBB, and means and standard deviations of biological triplicates are shown in comparison to cells expressing wild-type STAT3α-Myc (set to
1) (right panel).
doi:10.1371/journal.ppat.1005748.g002
Fig 3. Systematic deletion analysis of C-terminal IE1 residues 373–491. (A) Schematic overview of
amino acids 373–491 in the tested wild-type and mutant IE1 proteins. Positions of the low-complexity motifs
(acidic domains AD1-3 and serine/proline-rich region S/P), the SUMOylation site (K450) and the chromatin
tethering domain (CTD) are shown. (B) TetR cells without (w/o) or with inducible expression of the indicated
HA-tagged wild-type or mutant IE1 proteins were treated with dox for 72 h. Whole cell protein extracts were
prepared and analyzed by immunoblotting for IE1 (HA tag) and GAPDH. (C) TetR cells without (w/o) or with
inducible expression of the indicated HA-tagged wild-type or mutant IE1 proteins were treated with dox for 72
h. Whole cell extracts prepared in the presence of N-ethylmaleimide were used for immunoprecipitation with
anti-HA-agarose, and samples were analyzed by immunoblotting for IE1 (HA tag) and SUMO1.
doi:10.1371/journal.ppat.1005748.g003
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Collectively, these results indicate that the STAT3-related activities of IE1 do not involve
SUMOylation or nucleosome binding. Instead, residues in a region of IE1 that links the S/P
and AD2 low complexity stretches (amino acids 410 to 420) as well as residues within the AD2
motif (amino acids 421–445) are required for interaction with STAT3 and subsequent repres-
sion of STAT3-responsive genes.
Inhibition of STAT3-dependent and activation of STAT1-dependent
signaling by IE1 co-segregate
Our previous work has demonstrated that IE1 triggers a type II IFN-like response via a mecha-
nism that is dependent on tyrosine (Y701) phosphorylation and enhanced by serine (S727)
phosphorylation of STAT1 induced by the viral protein [21]. To investigate whether the
STAT1- and STAT3-related activities of IE1 are linked, we subjected our wild-type and mutant
IE1 expressing cell lines to immunoblotting for Y701- and S727-phosphorylated STAT1.
Again, all but the IE1dl410-420 and dl421-445 mutants induced STAT1 Y701 and S727 phos-
phorylation in a fashion comparable to the wild-type viral protein (Fig 5A). Cells expressing
these two mutants also exhibited lower overall STAT1 levels compared to cells expressing the
wild-type or other mutant proteins, most likely because pSTAT1 positively regulates its own
expression. Likewise, when tested for induction of genes representative of pSTAT1-responsive
type II ISGs (CXCL10 and CXCL11) by RT-qPCR, the IE1dl410-420 and dl421-445 proteins
were severely defective. All other mutants were active for CXCL10 and CXCL11 induction,
although IE1dl373-386 and dl387-394 displayed reduced and IE1dl476-491 protein increased
activities compared to the wild-type (Fig 5B). We suspect that mutations between amino acids
373 and 394 may indirectly affect IE1-STAT3 complex formation, perhaps by impacting the
viral protein’s overall structure. Conversely, increased nucleoplasmic localization may explain
why the CTD-deficient IE1 mutant (IE1dl410-420) is more potent than the chromatin-associ-
ated viral protein. We also observed that the IE1-dependent repression of genes responsive to
STAT3, IL6 or/and OSM tends to precede the activation of genes responsive to STAT1 or/and
IFNγ by IE1 (S3 Fig).
These results suggest that the effects IE1 exerts on the STAT1- and STAT3-dependent sig-
naling pathways are related and indicate that the former might depend on the latter.
Fig 4. Residues within IE1 region 410–445 are required for targeting of STAT3 and down-regulation of STAT3-responsive
genes. (A) TetR cells without (w/o) or with inducible expression of the indicated HA-IE1 proteins were treated with dox for 48 h. During
the final 24 h of dox treatment, cells were kept in medium with 0.5% FBS. Subcellular localization of endogenous STAT3α in IE1
expressing cells was analyzed by indirect immunofluorescence microscopy. Samples were simultaneously reacted with a rabbit
monoclonal antibody to STAT3α and a mouse monoclonal antibody to HA-tagged IE1, followed by incubation with a rabbit-specific
Alexa Fluor 594 conjugate and a mouse-specific Alexa Fluor 488 conjugate. Host cell nuclei were visualized by 4',6-diamidino-
2-phenylindole (DAPI) staining. Additionally, merge images of STAT3α, IE1 and DAPI signals are presented. (B) The percentage of
cells with i) predominantly nuclear STAT3α staining (N>C), ii) equally strong nuclear and cytoplasmic STAT3α staining (N = C) and iii)
predominantly cytoplasmic STAT3α staining (C>N) was determined for 100 randomly selected cells per sample described in (A). (C)
TetR cells without or with inducible expression of HA-tagged wild-type IE1 or IE1dl410-420 were treated with dox for 72 h and with
solvent (w/o) or IL6 plus IL6R (IL6/Rα) for 30 min. Cytoplasmic and nuclear extracts were prepared and analyzed by immunoblotting for
histone H2B, STAT2, STAT3α and IE1. (D) TetR cells without (w/o) or with inducible expression of HA-tagged wild-type IE1 or
IE1dl410-420 were treated with dox for 72 h. Whole cell extracts were prepared and used for immunoprecipitations (IPs) with anti-HA-
agarose. Samples of lysates and immunoprecipitates were analyzed by immunoblotting for IE1 and STAT3α. (E) TetR cells without (w/
o) or with inducible expression of HA-tagged wild-type IE1 or IE1dl410-420 were treated with dox for 72 h and with IL6 plus IL6R for 30
min. Samples were subjected to ChIP with rabbit polyclonal antibodies to STAT3 or normal rabbit IgG and primers specific for
sequences in the SOCS3 promoter or coding region. The percentage of output versus input DNA is presented as the difference
between STAT3 and normal IgG ChIPs. Means and standard deviations of two biological and two technical replicates are shown. (F)
TetR cells without (w/o) or with inducible expression of the indicated HA-tagged wild-type or mutant IE1 proteins were treated with dox
for 72 h. Relative mRNA expression levels were determined by RT-qPCRwith primers specific for the STAT3 target genes CXCL12
and SOCS3. Results were normalized to TUBB, and means and standard deviations of two biological and two technical replicates are
shown in comparison to IE1-negative TetR cells (set to 1).
doi:10.1371/journal.ppat.1005748.g004
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STAT3 depletion recapitulates and IL6ST or JAK1 depletion disrupts
IE1-induced expression of STAT1-responsive genes
In the next step, we addressed the mechanism underlying the proposed link between the
IE1-related effects on STAT3- and STAT1-dependent signaling. To this end, we used two
siRNA duplexes each to individually knock-down expression from three essential genes
(STAT3, IL6ST and JAK1) of the IL6-type pSTAT3 signaling pathway and examined the conse-
quences on IE1-mediated induction of pSTAT1-responsive type II ISGs (CXCL10 and GBP4).
Either of the target-specific siRNAs reduced the levels of the corresponding mRNA by80%,
compared to a non-specific siRNA, without significantly affecting the IE1 mRNA levels (Fig
6A–6C). Notably, STAT3 knock-down by either of the two specific siRNAs lead to a dramatic
increase in CXCL10 and GBP4 transcript levels (in the absence of IE1) and enhanced IE1-de-
pendent ISG induction. Conversely, IL6ST or JAK1 knock-down had little effect on CXCL10
and GBP4 transcript levels, but markedly reduced ISG induction by IE1 (Fig 6A–6C). In com-
parison, IFNGR1 knock-down affected ISG (CXCL9, CXCL10 and CXCL11) activation by IE1
only slightly (S4 Fig) confirming that this effect is largely independent from upstream compo-
nents of the type II IFN signaling pathway including IFNγ [21].
These results indicate that the pSTAT1-dependent IFNγ-like transcriptional response
observed in the presence of IE1 depends on upstream components of the IL6-type (but not
IFNγ-type) signaling pathway and may involve targeting of STAT3.
IE1 rewires an upstream IL6-type to a downstream IFNγ-like response
Based on the above results, we hypothesized that IE1 may redirect IL6-related signaling away
from STAT3 and towards STAT1 activation. In accordance with this hypothesis, IL6 triggered
robust and prolonged STAT1 Y701 phosphorylation in the presence of wild-type IE1, but not
in the presence of IE1dl410-420 or in the absence of the viral protein (Fig 7A and 7B). In fact,
the combination of IL6 and IE1 was at least equally efficient in mediating STAT1 activation as
Fig 5. Residues within IE1 region 410–445 are required for phosphorylation of STAT1 and up-regulation of IFNγ-responsive genes. (A)
TetR cells without (w/o) or with inducible expression of the indicated HA-tagged wild-type or mutant IE1 proteins were treated with dox for 72 h.
Whole cell protein extracts were prepared and analyzed by immunoblotting for IE1 (HA tag), pSTAT1 (Y701), pSTAT1 (S727), total STAT1 and
GAPDH. (B) TetR cells without (w/o) or with inducible expression of the indicated HA-tagged wild-type or mutant IE1 proteins were treated with
dox for 72 h. Relative mRNA expression levels were determined by RT-qPCR with primers specific for the STAT1 target genes CXCL10 and
CXCL11. Results were normalized to TUBB, and means and standard deviations of two biological and two technical replicates are shown in
comparison to IE1-negative TetR cells (set to 1).
doi:10.1371/journal.ppat.1005748.g005
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Fig 6. Knock-down of STAT3 recapitulates, while knock-down of IL6ST or JAK1 disrupts IE1-mediated induction of IFNγ-
stimulated genes. (A) TetR (w/o) or TetR-IE1 (IE1) cells were transfected with a control siRNA or two different siRNAs specific for
STAT3. From 48 h post siRNA transfection, cells were treated with dox for 72 h. Relative mRNA levels were determined by RT-qPCR for
STAT3, IE1 and the STAT1 target genes CXCL10 and GBP4. Results were normalized to TUBB, and means and standard deviations of
two biological and two technical replicates are shown in comparison to control siRNA-transfected TetR-IE1 cells (set to 1). (B) TetR (w/o)
or TetR-IE1 (IE1) cells were transfected with a control siRNA or two different siRNAs specific for IL6ST. From 48 h post siRNA
transfection, cells were treated with dox for 72 h. Relative mRNA levels were determined by RT-qPCR for IL6ST, IE1, CXCL10 and
GBP4. Results were normalized to TUBB, and means and standard deviations of two biological and two technical replicates are shown
in comparison to control siRNA-transfected TetR-IE1 cells (set to 1). (C). TetR (w/o) or TetR-IE1 (IE1) cells were transfected with a
control siRNA or two different siRNAs specific for JAK1. From 48 h post siRNA transfection, cells were treated with dox for 72 h. Relative
mRNA levels were determined by RT-qPCR for JAK1, IE1, CXCL10 and GBP4. Results were normalized to TUBB, and means and
standard deviations of two biological and two technical replicates are shown in comparison to control siRNA-transfected TetR-IE1 cells
(set to 1).
doi:10.1371/journal.ppat.1005748.g006
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Fig 7. IE1 switches an IL6-type to an IFNγ-like response. (A) TetR (w/o) or TetR-IE1 (IE1) cells were treated with dox for 72 h and with IL6
plus IL6R (IL6/Rα) for the indicated times. Whole cell protein extracts were prepared and analyzed by immunoblotting for IE1, total STAT1,
pSTAT1 (Y701), total STAT3α, pSTAT3 (Y705) and GAPDH. (B) TetR (w/o) or TetR-IE1 cells expressing HA-tagged wild-type IE1 or IE1dl410-
420 were treated with dox for 72 h and with solvent, IFNα, IFNγ or IL6 plus IL6R (IL6/Rα) for 24 h. Whole cell protein extracts were analyzed by
immunoblotting for IE1, total STAT1, pSTAT1 (Y701) and GAPDH. (C) TetR (w/o) or TetR-IE1 cells expressing HA-tagged wild-type IE1 or
IE1dl410-420 were treated with dox for 72 h and with solvent, IFNα, IFNγ or IL6 plus IL6R (IL6/Rα) for 24 h. Relative mRNA levels were
determined by RT-qPCR for the type I IFN/STAT2 target genes OAS1 and EIF2AK2 (protein kinase R) (left panels), the type II IFN/STAT1
target genes CXCL10 and CXCL11 (middle panels) and the IL6/STAT3 target genes CXCL12 and SOCS3 (right panels). Results were
normalized to TUBB, and means and standard deviations of biological triplicates are shown in comparison to solvent-treated TetR cells (set to
1).
doi:10.1371/journal.ppat.1005748.g007
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IFNγ. Consistently, IL6 also caused ~1,000-fold increased expression of pSTAT1-responsive
type II ISGs (CXCL10 and CXCL11) in cells with wild-type IE1 compared to cells with
IE1dl410-420 or no viral protein (Fig 7C). We further observed that IFNγ was more effective in
inducing STAT1 Y701 phosphorylation and type II ISG induction when wild-type IE1 was
expressed. Instead, wild-type IE1 inhibited induction of type I ISGs by IFNα in accordance
with previous reports [52–54] (Fig 7B and 7C). Finally, wild-type IE1 but not IE1dl410-420
inhibited both basal and cytokine-induced expression of IL6/STAT3-responsive genes
(CXCL12 and SOCS3) (Fig 7C).
From these results we conclude that IE1 disconnects upstream IL6-type from downstream
STAT3-dependent signaling, reconnecting it to downstream STAT1 signaling and related gene
expression.
hCMV infection rewires IL6-type to IFNγ-like signaling in an
IE1-dependent manner
To be able to test whether the IE1-STAT3 interaction diverts IL6 signaling also in the context
of infection, we derived a mutant virus (TBIE1dl410-420) specifically lacking the sequence
encoding IE1 amino acids 410 to 420 from a bacterial artificial chromosome (BAC) clone of
the hCMV TB40/E strain. In addition, a virus in which the mutated sequence was reverted to
wild-type (TBrvIE1dl410-420) was constructed. The integrity and identity of the BACs under-
lying the mutant and revertant viruses were verified in comparison to the wild-type (TBwt) by
restriction fragment and PCR analysis, respectively (S5 Fig). Following infection of MRC-5
cells, an increase in nuclear localization of STAT3 compared to mock-infected cells was
observed with the TBwt and TBrvIE1dl410-420 but not the TBIE1dl410-420 virus (S6 Fig). At
low input multiplicity, the TBIE1dl410-420 virus exhibited attenuated replication and
increased sensitivity to exogenous IFNβ compared to the TBwt and TBrvIE1dl410-420 viruses
(Fig 8A). At high multiplicity of infection, the IE1dl410-420 protein accumulated to similar
levels as the full-length protein expressed from TBwt or TBrvIE1dl410-420 (Fig 8B). However,
significant IL6-dependent STAT1 Y701 phosphorylation was only observed with the wild-type
and revertant but not the mutant virus at both early (24 h) and late times (72 h) post infection
(Fig 8B and S7A Fig). Upon TBwt infection, several type II ISGs (CXCL9, CXCL10, CXCL11
and IDO) exhibited varying degrees of activation at 24 h post infection in accordance with pre-
vious reports [21, 67–76]. Following addition of IL6 to the infected cells, expression of the four
tested ISGs increased by ~2- to>30-fold. This increase was significantly stronger in TBwt and
TBrvIE1dl410-420 compared to TBIE1dl410-420 infections (Fig 8C and S7B Fig).
These results indicate that the IE1-STAT3 interaction is not only sufficient to rewire
IL6-type to IFNγ-like signaling, but also largely required to mediate this response during
hCMV infection.
Rewired IL6-type to IFNγ-like signaling tempers hCMV replication
The phenotype of the TBdlIE1410-420 mutant virus (Fig 8A) suggests that the diverted signal-
ing linked to IE1-STAT3 interaction may be beneficial to hCMV replication. However, STAT3
knock-down turned out to inhibit replication of both TBwt and TBdlIE1410-420 (S8 Fig).
Moreover, STAT2 binding maps to a region overlapping IE1 amino acids 410–420 [53] and
TBdlIE1410-420 is hypersensitive to IFNβ (Fig 8A). Thus, the replication defect of
TBdlIE1410-420 may derive from either or both inhibition of type I IFN signaling (via STAT2
binding) or rewiring of IL6/IFNγ signaling (via STAT3 binding). To discriminate between the
consequences of STAT2 and STAT3 targeting by IE1, infections with EGFP expressing hCMV
strains were performed in human fibroblasts lacking any STAT2 protein. In the absence of
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STAT2, replication of the gTBIE1dl410-420 mutant did not differ from the wild-type (gTBwt)
and revertant (gTBrvIE1dl410-420) virus. Furthermore, addition of IL6 selectively reduced
the replication efficiency of gTBwt and gTBrvIE1dl410-420 but not gTBIE1dl410-420 (Fig 8D
and 8E).
These results indicate that the type II IFN-like response mediated by IL6-type cytokines in
the presence of IE1 moderates rather than promotes hCMV replication, revealing an unantici-
pated temperance activity encoded in the viral protein.
Discussion
Decades of research have established that hCMV IE1 is a promiscuous transcriptional activator
of viral and cellular genes [42, 65]. In contrast, evidence supporting transcriptional repression
by IE1 is much scarcer. Our study reveals that IE1 is as much a repressor as it is an activator of
host gene expression. This finding is unexpected and challenges the view that the viral protein
is essentially a transcriptional activator. Many of the genes found to be down-regulated by IE1
have been previously shown to be up-regulated by pSTAT3 or/and upstream regulators in this
pathway including cytokines of the IL6 family. Beyond that, we identified several new pSTAT3
targets among the genes that are subject to IE1 repression. We predict that many more of the
genes repressed by IE1 than those listed in Table 1 and marked as STAT3-responsive in
Table 2 will turn out to be activated by signaling via pSTAT3. Although, to our knowledge, this
is the first systematic genome-wide analysis of transcriptional repression by IE1, our results are
consistent with earlier findings linking the viral protein to down-regulation of the genes encod-
ing glial fibrillary acidic protein [77, 78] and SOCS3 [30], both of which are activated by
pSTAT3 [79–82]. Our results are also in line with previous reports on inhibition of IL6 signal-
ing by hCMV, although hCMV-dependent activation of IL6 signaling has also been observed
[30, 83]. The possibility that IL6 signaling is induced and subsequently blocked in cells hit by
infectious virus (expressing IE1), but induced without being blocked in bystanding cells hit by
non-infectious virus (not expressing IE1) may reconcile these seemingly conflicting findings.
Our conclusions regarding the mechanism underlying JAK-STAT-related transcriptional
repression and activation by IE1 result partly from the analysis of mutant proteins. These anal-
yses map all activities linked to repression of pSTAT3- and activation of pSTAT1-responsive
genes, including IE1-STAT3 complex formation, to a region between amino acids 410 and 445
in the C-terminal domain of the viral protein. This region contains residues upstream of and
Fig 8. IE1 rewires IL6 signaling to STAT1 activation during hCMV infection. (A) MRC-5 cells were infected with TBwt,
TBIE1dl410-420 or TBrvIE1dl410-420 at low input multiplicity (0.1 PFU/cell) in the absence (w/o) or presence of exogenous
IFNβ. Culture media were replaced every 24 h, and viral replication was assessed by qPCR-based relative quantification of
hCMV DNA from culture supernatants at the indicated times post infection with primers specific for the viral UL86 sequence.
Data are presented as means and standard deviations from three independent infections. (B) MRC-5 cells were mock-infected
or infected with TBwt, TBIE1dl410-420 or TBrvIE1dl410-420 at a high input multiplicity (5 PFU/cell). At 6 h post infection,
cultures were treated with solvent or IL6 plus IL6R (IL6/Rα). At 24 h post infection, whole cell protein extracts were prepared
and analyzed by immunoblotting for IE1/IE2, total STAT1, pSTAT1 (Y701) and GAPDH. (C) MRC-5 cells were mock-infected
or infected with TBwt, TBIE1dl410-420 or TBrvIE1dl410-420 at a high input multiplicity (5 PFU/cell). At 6 h post infection,
cultures were treated with solvent or IL6 plus IL6R (IL6/Rα). At 24 h post infection, relative mRNA levels were determined by
RT-qPCR for the STAT1 target genes CXCL9, CXCL10, CXCL11 and IDO. Results were normalized to TUBB, and means and
standard deviations of biological triplicates are shown in comparison to solvent-treated mock-infected cells (set to 1). (D)
STAT2-deficient human skin fibroblasts were infected with gTBwt, gTBIE1dl410-420 or gTBrvIE1dl410-420 at low input
multiplicity (0.1 PFU/cell) in the absence (w/o) or presence of IL6 plus IL6Rα (IL6/Rα). Every 48 h, half of the culture media was
replaced and viral replication was assessed at day 6 post infection by fluorescence microscopy. (E) STAT2-deficient human
skin fibroblasts were infected with gTBwt, gTBIE1dl410-420 or gTBrvIE1dl410-420 at low input multiplicity (0.1 PFU/cell) in the
absence (w/o) or presence of IL6 plus IL6Rα (IL6/Rα). Every 48 h, half of the culture media was replaced and viral replication
was assessed by qPCR-based relative quantification of hCMV DNA from culture supernatants with primers specific for the viral
UL86 sequence. Data are presented as means and standard deviations from two biological and two technical replicates.
doi:10.1371/journal.ppat.1005748.g008
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including AD2, a low complexity motif rich in glutamic and aspartic acid. Other interactions
mapped to the C-terminal domain of IE1 include binding to chromatin/nucleosomes via the
CTD (amino acids 476–491) [59, 61, 62], conjugation to SUMO1 via lysine 450 [57, 58, 84]
and binding to STAT2 [52–54]. The CTD proved to be necessary for SUMO1 conjugation,
confirming results from previous reports [85, 86] and suggesting that nucleosome binding may
be a prerequisite for SUMOylation of IE1. However, nucleosome interaction and SUMOylation
were not required for the observed effects IE1 exerts on JAK-STAT signaling. In fact, SUMOy-
lation has been previously shown to negatively regulate the IE1-STAT2 interaction [54]. The
relationship between the IE1-STAT2 and IE1-STAT3 interactions is discussed below.
Most previous work has suggested that IE1 activates gene expression through various chro-
matin-directed mechanisms including recruitment of transcription factors [87–89], inhibition
of transcription repressors [90–92], acetylation of histones [93] or reorganization of nucleo-
somes [94]. Our present study demonstrates that IE1 also passively modulates transcription
upstream of chromatin by linking repression of STAT3- to activation of STAT1-responsive
human genes. Our results suggest a model (Fig 9) where STAT3, which shuttles through the
nucleus independent of phosphorylation [5], forms a nuclear resident complex with IE1. The
nuclear retention imposed on STAT3 precludes the protein from being Y705-phosphorylated
by its cytoplasmic kinase JAK1. Thus, the STAT3 accumulating in the nucleus in the presence
of IE1 is mostly unphosphorylated [30] and therefore unable to bind to and activate pSTAT3-
dependent target genes. It remains to be investigated whether IE1 also prevents DNA binding
Fig 9. Model linking repression of STAT3-responsive to activation of STAT1-responsive genes by IE1. (Left panel) Binding of IL6 family
cytokines (or growth factors) to the extracellular IL6R subunits leads to tyrosine phosphorylation of JAK1 (and other JAK family kinases)
associated with the IL6ST receptor subunits. In turn, JAK1 phosphorylates tyrosine residues in IL6ST creating binding sites for STAT3. Following
tyrosine phosphorylation by JAK1, pSTAT3 forms active dimers capable of binding DNA. These STAT3 dimers accumulate in the nucleus and
activate target gene transcription. STAT1 remains mostly unphosphorylated, cytoplasmic and excluded from binding to the receptor in the
absence of IE1. (Right panel) In the presence of IE1, cytoplasmic STAT3 pools become depleted due to formation of a nuclear IE1-STAT3
complex. In the absence of cytoplasmic STAT3, STAT1 binds to the activated IL6ST and undergoes JAK1-mediated tyrosine phosphorylation
resulting in active dimers. These STAT1 dimers accumulate in the nucleus, bind to DNA and activate target gene expression resulting in an IFNγ-
like response triggered by IL6-type cytokines.
doi:10.1371/journal.ppat.1005748.g009
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of Y705-phosphorylated STAT3. In the context of activated IL6-type signaling, the nuclear
IE1-STAT3 interaction becomes evident as transcriptional repression of pSTAT3-responsive
genes. In addition to mediating this repression, the IE1-STAT3 interaction also triggers tran-
scriptional activation. We propose that, in the absence of cytoplasmic STAT3, JAK1 mediates
Y701 phosphorylation of STAT1 leading to nuclear accumulation of pSTAT1 and activation of
type II ISGs. Type II ISG activation by IE1 has been observed before [21], but seems to contra-
dict a recent report showing that the viral protein disrupts type II IFN signaling by an unknown
mechanism [95]. It appears that this mechanism involves indirect consequences of IE1-STAT2
rather than direct IE1-STAT1 binding, just as the activation of type II ISGs is an indirect conse-
quence of the IE1-STAT3 interaction. In fact, direct binding between IE1 and STAT1 has not
been demonstrated, although the two proteins may indirectly associate via STAT heterodimer
formation [52, 63]. In any case, our model is fully consistent with the fact that depletion of
STAT3 phenocopies the IE1-related effects we observe, and that these effects are largely depen-
dent on pSTAT1 [21], IL6ST and JAK1 but not IFNGR1. It is also in line with the observation
that IE1 promotes STAT1 phosphorylation and nuclear accumulation [21]. Finally, the model
fits the idea that IFNγ‐like responses depend on pSTAT1, but not necessarily on signaling
through the cognate receptor. In fact, activation of STAT1 through foreign chimeric receptors
proved to be almost as effective in mediating major aspects of an IFNγ response in human cells
as activation through the natural receptor [96]. It has also been shown that phosphotyrosine
motifs in both IFNGR and IL6ST can serve as docking sites for the STAT1 SH2 domain [97–
100]. Two of the four phosphotyrosine motifs in IL6ST are specific for STAT3 while two can
recruit both STAT3 and STAT1 with similar affinities [100]. The absence of STAT3 may
release competition for the common docking sites, favoring recruitment and activation of
STAT1. In accordance with this idea, IL6 triggered an IFNγ-like response including prolonged
activation of STAT1 and induction of multiple type II ISGs in mouse cells lacking STAT3 [15].
A similar type II ISG response to STAT3 depletion was observed in human cells (this work).
The STAT3/STAT1 cross-regulation seems to result in an integrated signal that can be fine-
tuned depending on the cellular context, strongly arguing for flexible rather than fixed wiring
of these pathways [14, 16, 17, 101–103].
We anticipate that future work will recognize at least a subset of genes repressed or activated
by IE1 as important factors in hCMV infection. In fact, several targets of IE1 repression identi-
fied in this study have already been ascribed critical roles in the hCMV life cycle. To give but
one example, IFNγ-inducible protein 16 (IFI16) acts as a foreign DNA sensor and restriction
factor for hCMV [104, 105], suggesting that IE1 might promote viral replication by limiting its
expression. In accordance with this speculation, replication of an IE1 mutant hCMV
(TBIE1dl410-420) deficient for STAT3/STAT1 pathway diversion is attenuated compared to
wild-type and revertant viruses. It should be noted, however, that the attenuated phenotype of
the TBIE1dl410-420 virus does not necessarily result from repression of STAT3-responsive
genes. In fact, this study mapped STAT3 binding between amino acids 410 and 445, while our
previous work mapped STAT2 binding between amino acids 373 and 445 in IE1 [51]. Thus,
STAT3 and STAT2 seem to bind to the same or closely adjoining sites in IE1, making it diffi-
cult to work out the extent by which either interaction contributes to the observed replication
defect. That said, the replication defect exhibited by TBIE1dl410-420 in normal fibroblasts was
entirely rescued in STAT2-deficient cells. Moreover, TBIE1dl410-420 proved to be more sensi-
tive to exogenous IFNβ compared to wild-type and revertant viruses in normal fibroblasts.
These observations indicate that the attenuation of TBIE1dl410-420 results from the lack of
IE1-STAT2 interaction, which would normally promote viral replication by inhibiting type I
IFN signaling. In contrast, the type II IFN-like response linked to IE1-STAT3 interaction
appears to moderate rather than promote hCMV replication consistent with reports that IFNs
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govern viral latency, at least in murine cytomegalovirus (mCMV) [106, 107]. We are therefore
tempted to speculate that, by imparting a low-level chronic IFNγ-like response, IE1 might con-
tribute to viral quiescence in latently infected cells exposed to cytokines or growth factors that
activate IL6ST. This idea adds to the emerging concept that IE1, a protein traditionally linked
exclusively to the viral productive cycle, may also have an important role in hCMV latency
[41, 101].
IL6 and IFNγ are among the most pivotal cytokines in shaping innate and adaptive host
responses to infectious pathogens [7, 13]. In many instances, the two cytokines and their path-
ways have been associated with the outcomes of hCMV or mCMV infection and pathogenesis
[30, 108–113]. In addition to IL6-type cytokines, many other important factors signal via the
IL6ST-JAK1-STAT3 axis. These factors include GCSF and IL10, both of which have been
linked to hCMV infection including viral latency and reactivation [114–116]. Signaling
through STAT3 or STAT1 usually results in distinct and sometimes opposing outcomes. For
instance, STAT1 tends to promote apoptosis in a variety of cell types whereas STAT3 typically
has anti-apoptotic effects. Likewise, STAT1 usually acts anti-proliferative while STAT3 rather
promotes cellular proliferation [14, 17]. By merging two major signaling pathways with diverse
actions in many cell and tissue types, IE1 may impact hCMV infection and pathogenesis in sur-
prising ways that future work will explore.
Materials and Methods
Plasmids
The pMD2.G and psPAX2 packaging vectors for lentivirus production were obtained from
Addgene (plasmids #12259 and #12260, respectively). The lentiviral plasmid pLKOneo.CMV.
EGFPnlsTetR, encoding the tetracycline repressor linked to a nuclear localization signal and
the enhanced green fluorescent protein (EGFP) [117], was kindly provided by Roger Everett
(University of Glasgow). Plasmids pCMV.TetO.cIE1 and pLKO.DCMV.TetO.cIE1 (herein
referred to as pLKO.DCMV.TetO.IE1), expressing hCMV (Towne) IE1 under the control of a
tetracycline- or dox-inducible promoter, have been described [21]. Variants of these plasmids
encoding wild-type IE1 linked to an N-terminal hemagglutinin (HA) epitope tag (pLKO.
DCMV.TetO.HA-IE1) or HA-tagged IE1 deletion mutants were constructed by standard
PCR (IE1, IE1dl476-491, IE19, NLS-IE1dl1-404, 2×Stop-IE1) or overlap extension PCR
(IE1dl373-386, IE1dl387-394, IE1dl395-409, IE1dl410-420, IE1dl421-445, IE1dl446-450 and
IE1dl451-475) using oligonucleotide primers listed in Table 3. For each new construct, the
entire IE1-specific nucleotide sequence was verified by DNA sequencing. The lentiviral plas-
mids used for inducible expression of human STAT3- or firefly luciferase-specific shRNAs
(shSTAT3_1, shSTAT3_2 and shLUC) were generated by ligating annealed oligonucleotides
(Table 3) to EcoRI- and AgeI-digested Tet-pLKO-puro (Addgene plasmid #21915), and the
resulting constructs were verified by DNA sequencing.
First strand cDNA of the full-length human STAT3α coding sequence was prepared from
total RNA extracted fromMRC-5 cells using an oligo(dT)20 primer. The STAT3α cDNA was
linked to a C-terminal Myc epitope tag and PCR-amplified using oligonucleotide primers #961
and #962 (Table 3). The purified PCR product was ligated toHpaI-digested, dephosphorylated
retroviral vector pLHCX (Clontech, 631511) resulting in plasmid pLHCX-STAT3α-Myc.
QuikChange site-directed mutagenesis of pLHCX-STAT3α-Myc using oligonucleotide primers
#1051 and #1052 (Table 3) resulted in plasmid pLHCX-STAT3α_Y705F-Myc encoding a
trans-dominant negative STAT3α-Myc variant resistant to phosphorylation at Y705 [66]. For
both new constructs, the correct orientation and nucleotide sequence of the STAT3 insert were
verified by DNA sequencing.
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Table 3. Oligonucleotides used in this study.
# Sequence (5‘!3‘)1 Use2
151 CTCTCCTAGTGTGGATGACC PCR (pTBwt)
PCR (pTBIE1dl410-420)
PCR (pTBrvIE1dl410-420)
363 TATCAGCAGTACCAGGATGC RT-qPCR (TUBB)
364 TGAGAAGCCTGAGGTGATG RT-qPCR (TUBB)
386 TCCTAGTGTGGATGACCTACGGTACACTTTGGCCACCGCTGGTG pCMV.TetO.HA-IE1dl373-386
387 CACCAGCGGTGGCCAAAGTGTACCGTAGGTCATCCACACTAGGA pCMV.TetO.HA-IE1dl373-386
388 CACTTTGGCCACCGCTGGTGCCGCGACTATCCCTCTGTCCTCAG pCMV.TetO.HA-IE1dl395-409
389 CTGAGGACAGAGGGATAGTCGCGGCACCAGCGGTGGCCAAAGTG pCMV.TetO.HA-IE1dl395-409
390 TCTGTCCTCAGTAATTGTGGCTACTGTGTCTGTCAAGTCTGAGC pCMV.TetO.HA-IE1dl421-445
391 GCTCAGACTTGACAGACACAGTAGCCACAATTACTGAGGACAGA pCMV.TetO.HA-IE1dl421-445
392 GGAGGACACTGTGTCTGTCAAGGGAGGCAAGAGCACCCACCCTA pCMV.TetO.HA-IE1dl451-475
393 TAGGGTGGGTGCTCTTGCCTCCCTTGACAGACACAGTGTCCTCC pCMV.TetO.HA-IE1dl451-475
401 TGAGGAAGAGGCTATTGTAGCCAGCTCCTCTGATTCTCTGGTGT pCMV.TetO.HA-IE1dl387-394
402 ACACCAGAGAATCAGAGGAGCTGGCTACAATAGCCTCTTCCTCA pCMV.TetO.HA-IE1dl387-394
430 CTCACTACATGTGTGGAA PCR (pgTBwt)
PCR (pgTBIE1dl410-420)
PCR (pgTBrvIE1dl410-420)
467 CTTGTGGCTGATGTGAATGC RT-qPCR (IFI16)
468 AGGAGTTACGCTGGCACTTC RT-qPCR (IFI16)
471 TCCCTAAGACCACCAATG RT-qPCR (IE1)
472 GAGCACTGAGGCAAGTTC RT-qPCR (IE1)
484 TTGCAGAATTCTTACTGGTCAGCCTTGCTTCTAG pCMV.TetO.HA-NLS-IE1dl1-404
533 TCCACGTGTTGAGATCATTGC RT-qPCR (CXCL10)
534 TCTTGATGGCCTTCGATTCTG RT-qPCR (CXCL10)
535 CAAGGCTTCCCCATGTTCA RT-qPCR (CXCL11)
536 CCCAGGGCGTATGCAAAGA RT-qPCR (CXCL11)
537 GCTCCAAGCAGTCCTTTCAC RT-qPCR (GBP4)
538 GTGGTGGCTCATGCCTAAAT RT-qPCR (GBP4)
598 AGTGAGTAAGGCTGGGCAGA RT-qPCR (STAT3)
599 AAGGCACCCACAGAAACAAC RT-qPCR (STAT3)
672 CATCAATCATCACCCTGTGG RT-qPCR (JAK1)
673 CCAGCTACCTCCAAGCAAAC RT-qPCR (JAK1)
688 CTGGCGGCTATAAACCTAACC RT-qPCR (OAS1)
689 GTTCTGTGAAGCAGGTGGAGA RT-qPCR (OAS1)
690 ATGATGGAAAGCGAACAAGG RT-qPCR (EIF2AK2)
691 CAGCAAGAATTAGCCCCAAA RT-qPCR (EIF2AK2)
694 GATACTGAATTCTTACTGGTCAGCCTTGCTTCTAGT pCMV.TetO.HA-IE1wt
pCMV.TetO.HA-IE1dl373-386
pCMV.TetO.HA-IE1dl387-394
pCMV.TetO.HA-IE1dl395-409
pCMV.TetO.HA-IE1dl410-420
pCMV.TetO.HA-IE1dl421-445
pCMV.TetO.HA-IE1dl446-450
pCMV.TetO.HA-IE1dl451-475
pCMV.TetO.HA-IE19
pCMV.TetO.HA-2×Stop-IE1wt
(Continued)
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Table 3. (Continued)
# Sequence (5‘!3‘)1 Use2
695 GATACTGAATTCTTAAGAGGCGGTGGGTTCCTCAGCACC pCMV.TetO.HA-IE1dl476-491
749 GGCCACTCTTCAGCATCTC RT-qPCR (SOCS3)
750 ATCGTACTGGTCCAGGAACTC RT-qPCR (SOCS3)
771 ACTTTCTTCCTGATCACTGTTCTCGGGTACAGGGGACTCTGGGGGTGA pCMV.TetO.HA-IE1dl410-420
772 TCACCCCCAGAGTCCCCTGTACCCGAGAACAGTGATCAGGAAGAAAGT pCMV.TetO.HA-IE1dl410-420
773 CTCTATCTCAGACACTGGCTCAGAGTCCTCCCGCTCCTCCTGAGCACC pCMV.TetO.HA-IE1dl446-450
774 GGTGCTCAGGAGGAGCGGGAGGACTCTGAGCCAGTGTCTGAGATAGAG pCMV.TetO.HA-IE1dl446-450
809 GATACTAAGCTTGCCACCATGTATCCTTACGACGTGCCTGACTACGCC
GAGTCCTCTGCCAAGAGAAAGATG
pCMV.TetO.HA-IE1wt
pCMV.TetO.HA-IE1dl373-386
pCMV.TetO.HA-IE1dl387-394
pCMV.TetO.HA-IE1dl395-409
pCMV.TetO.HA-IE1dl410-420
pCMV.TetO.HA-IE1dl421-445
pCMV.TetO.HA-IE1dl446-450
pCMV.TetO.HA-IE1dl451-475
pCMV.TetO.HA-IE1dl476-491
pCMV.TetO.HA-IE19
872 GCGTTTAATGTCGTCGCTCAA qPCR (hCMV UL86)
873 CAGCCTACCCGTACCTTTCCA qPCR (hCMV UL86)
880 AAACCTTTGAACAAGTGACCGAGGATTGCAACGAGAACCCCGAA
AAAGATGTCCTGGCAGAACTCGGTAAGT
pTBrvIE1dl410-420
pgTBrvIE1dl410-420
881 ATAAGAAGACACGGGAGACTTAGTACGGTTTCACAGGCGTGACAC
GTTTATTGAGTAGGATTACAGAGTATA
pTBrvIE1dl410-420
pgTBrvIE1dl410-420
916 GATACTAAGCTTGCCACCATGTATCCTTACGACGTGCCTGACTACGC
CTAGTGATCTGCCAAGAGAAAGATG
pCMV.TetO.HA-2×Stop-IE1wt
923 GATACTAAGCTTGCCACCATGTATCCTTACGACGTGCCTGACTACGC
CCCCAAGAAGAAGAGAAAGGTGGAGTCCCCTGTACCCGCGACTATC
pCMV.TetO.HA-NLS-IE1dl1-404
927 GGCCGGTGCTACTGGAATCGATAC PCR (pTBwt)
PCR (pTBIE1dl410-420)
PCR (pTBrvIE1dl410-420)
961 P-GCCACCATGGCCCAATGGAATCAGCTACAG pLHCX-STAT3α-Myc
962 P-TCACAGATCCTCTTCTGAGATGAGTTTCTGCTCCATGGGGGAGGT
AGCGCACTCCGA
pLHCX-STAT3α-Myc
1029 AGCCTTTCTCTGCTGCGAGT ChIP (SOCS3 promoter)
1030 CCCGATTCCTGGAACTGC ChIP (SOCS3 promoter)
1031 GGAATGTAGCAGCGATGGAA ChIP (SOCS3 coding region)
1032 GCCCTGTCCAGCCCAATAC ChIP (SOCS3 coding region)
1041 CAGGGTTTCAGGTTCCAATC RT-qPCR (CXCL12)
1042 CACCAGGACCTTCTGTGGAT RT-qPCR (CXCL12)
1043 ACGGCTTCCAGGTTAAGGTT RT-qPCR (C4A)
1044 GTGCAGGACTTGGGTGATCT RT-qPCR (C4A)
1047 AAGTAGGGTTCAGCCAAAGC RT-qPCR (CHL1)
1048 ACGTGAACCTGTTCTACATACC RT-qPCR (CHL1)
1049 TGTCATCATCGTGGGCAACA RT-qPCR (RASL11A)
1050 CCAGCTCATTGGCTAGCTGA RT-qPCR (RASL11A)
1051 GTAGCGCTGCCCCATTCCTGAAGACCAAG pLHCX-STAT3α_Y705F-Myc
1052 CTTGGTCTTCAGGAATGGGGCAGCGCTAC pLHCX-STAT3α_Y705F-Myc
1075 GCTGCTTGGGTTCTCCATAG RT-qPCR (IL6ST)
(Continued)
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Table 3. (Continued)
# Sequence (5‘!3‘)1 Use2
1076 GCTCTGGCTTCGTATCTGTT RT-qPCR (IL6ST)
1094 CTCTGATTCTCTGGTGTCACCCCCAGAGTCCCCTGTACCCGAGAACAG
TGATCAGGAAGATAGGGATAACAGGGTAATCGATTT
pTBIE1dl410-420
pgTBIE1dl410-420
1095 CCTCATCACTCTGCTCACTTTCTTCCTGATCACTGTTCTCGGGTACA
GGGGACTCTGGGGGCCAGTGTTACAACCAATTAACC
pTBIE1dl410-420
pgTBIE1dl410-420
1098 P-CCGGGTGCGTTGCTAGTACCAACCTCGAGGTTGGTACTAGCAACGCACTTTTT Tet-pLKO-puro.shLUC
1099 P-AATTAAAAAGTGCGTTGCTAGTACCAACCTCGAGGTTGGTACTAGCAACGCAC Tet-pLKO-puro.shLUC
1102 P-CCGGGCCTCAAGATTGACCTAGACTCGAGTCTAGGTCAATCTTGAGGCTTTTT Tet-pLKO-puro.shSTAT3_1
1103 P-AATTAAAAAGCCTCAAGATTGACCTAGACTCGAGTCTAGGTCAATCTTGAGGC Tet-pLKO-puro.shSTAT3_1
1134 P-CCGGAGTCAGGTTGCTGGTCAAACTCGAGTTTGACCAGCAACCTGACTTTTTT Tet-pLKO-puro.shSTAT3_2
1135 P-AATTAAAAAAGTCAGGTTGCTGGTCAAACTCGAGTTTGACCAGCAACCTGACT Tet-pLKO-puro.shSTAT3_2
1165 CTCTGGGGCAACTTCCTCTA PCR (pgTBwt)
PCR (pgTBIE1dl410-420)
PCR (pgTBrvIE1dl410-420)
1291 TATTGAAAGCGGAGAAATGCC RT-qPCR (MYOCD)
1292 GAAGATCTGGGTATCTTTGGGA RT-qPCR (MYOCD)
1293 CACGATGTGAATTGGTTGGT RT-qPCR (PDK4)
1294 TGCCTTTGAGTGTTCAAGGA RT-qPCR (PDK4)
1295 AATCCTTGGAGCCCTAACAG RT-qPCR (TMOD1)
1296 AGCAGTGCATTATCAGGGT RT-qPCR (TMOD1)
1297 GCGTATGTGAAATTCGTCCCT RT-qPCR (LRRN1)
1298 TCCTTGTTAAGCGGAGGTCAT RT-qPCR (LRRN1)
1299 CTTCAAAGCTTTGGTCCAC RT-qPCR (AKR1C3)
1300 CCAATTGAGCTTTCTTCAGTG RT-qPCR (AKR1C3)
1301 AGAAAGGATTCCCTCCTCCA RT-qPCR (RGS5)
1302 CAGCCAATCCAGAGCCTTAG RT-qPCR (RGS5)
1303 ATCACATTCCAGCAGGCTTC RT-qPCR (STC1)
1304 CCTGAAGCCATCACTGAGGT RT-qPCR (STC1)
1305 CTGCTGCACATCGTCATTGAC RT-qPCR (EDNRB)
1306 GCTCCAAATGGCCAGTCCT RT-qPCR (EDNRB)
1307 GCATACAGGGACAACAAACAAC RT-qPCR (PDE1A)
1308 TCTCAAGGACAGAGCGATCAT RT-qPCR (PDE1A)
1309 ACAGGTCCAACCTACATGCC RT-qPCR (TSPAN2)
1310 TGAGCTGGAGCTTAACACTGAT RT-qPCR (TSPAN2)
1311 AGTATCGCTACTTCAAAGGGT RT-qPCR (GPCPD1)
1312 CAACACCATTGTGGATTCCA RT-qPCR (GPCPD1)
1315 GAAATGGTAATCCAGCTCCTG RT-qPCR (PTGFR)
1316 AATGTTGGCCATTGTAACCAG RT-qPCR (PTGFR)
1317 TGAAATGTAAATGGTCCTGTCG RT-qPCR (HRSP12)
1318 GTCGTCCTTGATCAGAAGGG RT-qPCR (HRSP12)
1325 TTCACAGGCTATCCAAAATTCA RT-qPCR (RGS18)
1326 TTTGACAAACTGCTTTCCCA RT-qPCR (RGS18)
1 P-, 5‘ phosphate.
2 RT-qPCR-based quantiﬁcation of the indicated mRNA, qPCR-based hCMV or ChIP quantiﬁcation or PCR-based construction of the indicated plasmid or
BAC.
doi:10.1371/journal.ppat.1005748.t003
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To generate expression plasmids for proteins linked to N-terminal mCherry, the mCherry
cDNA was PCR-amplified from plasmid pIM-Asf1B-mCherry (kindly provided by Jean-Yves
Thuret, Paris-Sud University) using oligonucleotide primers #1201 and #1202 (Table 3) and
ligated to BglII- and HindIII-digested pCMV.TetO.HA-IE19. The HA-IE19 insert of the result-
ing construct was released withHindIII and EcoRI and replaced with the HA-IE1 coding
sequences of plasmids pCMV.TetO.HA-IE1, pCMV.TetO.HA-2×Stop-IE1 and pCMV.TetO.
HA-NLS-IE1dl1-404. The resulting constructs were verified by DNA sequencing.
Plasmid templates pLAY2 and pUC-MIE-Kan_I-SceI for generation of mutant and rever-
tant hCMV TB40/E BACs by en passantmutagenesis, kindly provided by Karsten Tischer
(Freie Universität Berlin), have been described [62, 94, 118].
Antibodies
The primary antibodies used in this work were as follows: mouse anti-HA (Covance, MMS-
101P), mouse anti-IE1 ([119], 1B12), mouse anti-IE1/IE2 (Millipore, MAB810R), mouse anti-
Myc (Santa Cruz Biotechnology, sc-40), rabbit anti-glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) (Abcam, ab9485), rabbit anti-H2B (Abcam, ab1790), rabbit anti-STAT1 p84/
p91 (Santa Cruz Biotechnology, sc-346), rabbit anti-STAT1α p91 (Santa Cruz Biotechnology,
sc-345), rabbit anti-STAT2 (Santa Cruz Biotechnology, sc-22816), rabbit anti-STAT3 (Santa
Cruz Biotechnology, sc-482x), rabbit anti-STAT3α (Cell Signaling Technologies, 8768), rabbit
anti-pSTAT1 (Y701) (Cell Signaling Technologies, 9171), rabbit anti-pSTAT1 (S727) (Cell Sig-
naling Technologies, 9177), rabbit anti-pSTAT3 (Cell Signaling Technologies, 9145), rabbit
anti-SUMO1 (Santa Cruz Biotechnology, sc-9060) and mouse anti-α-tubulin (TUBA)
(Thermo Fisher Scientific, A-11126).
The following secondary antibodies were used: peroxidase-conjugated goat anti-mouse
immunoglobulin G (IgG) (Dianova, 115-035-166) or goat anti-rabbit IgG (Dianova, 111-035-
144) for immunoblotting, and highly cross-adsorbed Alexa Fluor 488-conjugated goat anti-
mouse IgG (Thermo Fisher Scientific, A-11001) or Alexa Fluor 594-conjugated goat anti-rabbit
IgG (Thermo Fisher Scientific, A-11037) for immunofluorescence.
Cells and retroviruses
MRC-5 human embryonic lung fibroblasts (American Type Culture Collection, CCL-171),
STAT2-deficient primary skin fibroblasts from a 5-year-old child with a history of dissemi-
nated vaccine-strain measles [120] (kindly provided by Sophie Hambleton, Newcastle Univer-
sity) and Phoenix-Ampho retrovirus packaging cells (kindly provided by Garry Nolan,
Stanford University) were maintained in Dulbecco's Modified Eagle’s Medium (DMEM) sup-
plemented with 10% fetal calf serum (FCS), 100 units/ml penicillin and 100 μg/ml streptomy-
cin. The human embryonic kidney cell line 293T (GenHunter, Q401) was cultured in the same
medium containing 400 μg/ml G418 sulfate. All cultures were regularly screened forMyco-
plasma sp. using an in-house qPCR assay. Where applicable, cells were treated with 1,000 U/ml
recombinant human IFNα A/D (R&D Systems, 11200), 1,000 U/ml IFNβ1α (Miltenyi Biotec,
130-107-888), 1,000 U/ml recombinant human IFNγ (R&D Systems, 285-IF), 100 ng/ml
recombinant human OSM (R&D Systems, 295-OM-010) or 100 ng/ml recombinant human
IL6 (R&D Systems, 206-IL-010) plus 100 ng/ml recombinant human IL6Rα (R&D Systems,
227-SR-025) for the indicated durations. Fibroblasts are normally unresponsive to IL6, since
they have little or no IL6R (also known as IL6Rα). However, soluble IL6R can bind IL6 with
similar affinity as membrane-bound IL6R and the complex of IL6 and soluble IL6R can interact
with and signal through IL6ST (also known as IL6Rβ or gp130).
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Production of replication-deficient retroviral particles, retrovirus infections and selection of
stable cell lines were performed as previously described [21] with minor modifications. Lenti-
viral particles were generated by transient transfection of 293T cells using calcium phosphate
co-precipitation [121]. Recombinant viruses were collected 48 h after transfection and used for
two consecutive transductions of 4 h each. To generate TetR cells, low-passage MRC-5 cells
were transduced with pLKOneo.CMV.EGFPnlsTetR-derived lentiviruses and selected with
G418 sulfate (0.3 mg/ml). To generate TetR-IE1 cells, TetR cells were transduced with pLKO.
DCMV.TetO.HA-IE1-derived lentiviruses and selected with puromycin (1 μg/ml). TetR cells
were maintained in medium containing G418 sulfate (0.3 mg/ml), while TetR-IE1 cells were
cultured in the presence of both G418 sulfate (0.3 mg/ml) and puromycin (1 μg/ml). To induce
IE1 expression, cells were treated with dox (Clontech, 631311) at a final concentration of 1 μg/
ml. To generate cells with inducible expression of human STAT3- or firefly luciferase-specific
shRNAs, MRC-5 cells were transduced with Tet-pLKO-puro.shSTAT3_1-, Tet-pLKO-puro.
shSTAT3_2- or Tet-pLKO-puro.shLUC-derived lentiviruses and selected in medium contain-
ing puromycin (1 μg/ml). To induce shRNA expression, cells were treated with 1 μg/ml dox. At
least half of the culture medium was replaced every 48 h with fresh dox added to maintain sta-
ble shRNA expression. To generate cells constitutively expressing STAT3α-Myc proteins, TetR
cells were infected with pLHCX-derived retroviruses encoding STAT3α-Myc or STA-
T3α_Y705F-Myc and selected in medium containing hygromycin B (0.2 mg/ml).
hCMVmutagenesis and infection
Wild-type virus of the low passage hCMV strain TB40/E (TBwt) was derived from
TB40-BAC4 [122], kindly provided by Christian Sinzger (Ulm University). A modified version
of this BAC with an SV40-EGFP-BGH PolyA cassette inserted between the US34 and TRS1
genes [123] was kindly provided by Felicia Goodrum (University of Arizona) and used to gen-
erate the EGFP expressing TB40/E wild-type virus gTBwt. Mutant BACs encoding IE1 with
internal deletion of amino acids 410 to 420 (pTBIE1dl410-420 and pgTBIE1dl410-420) and
corresponding revertant BACs (pTBrvIE1dl410-420 and pgTBrvIE1dl410-420) were generated
from pTBwt or pgTBwt by markerless en passantmutagenesis, as previously described [62, 94]
using plasmids pLAY2 and pUC-MIE-Kan_I-SceI and oligonucleotide primers listed in
Table 3. The identity and integrity of each BAC were verified by DNA sequencing of the modi-
fied region and restriction fragment length analysis following digestion with EcoRI, respec-
tively. Viruses were reconstituted and virus stocks produced upon electroporation of MRC-5
cells with BAC DNA following standard protocols. Titers were determined by plaque assay,
and quantification of intracellular viral genome equivalents was performed as described [53]
except that cells were cultured in the presence of phosphonoacetic acid (0.2 mg/ml) for 18 h
before DNA isolation and qPCR analysis. MRC-5 lung and STAT2-deficient skin fibroblasts
were grown to confluency, serum-starved in DMEM containing 0.5% FBS for 24 h and infected
in medium with 0.5% FBS. After 6 h the inoculum was removed, cells were rinsed with pre-
warmed DMEM and cultured in serum-reduced (0.5% FBS) DMEM.
RNA interference
Silencer Select siRNAs (chemically modified, 21-mer, locked nucleic acid, double-stranded
RNAs; Thermo Fisher Scientific) at a final concentration of 30 nM were introduced into cells
using the Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific) and following the
manufacturer’s protocols. Briefly, exponentially growing cells were seeded either in 12-well
dishes at 2.5×105 cells/well for RNA analyses or in 6-well dishes at 5×105 cells/well for protein
analyses. Transfections were performed in Opti-MEM I Reduced SerumMedium (Thermo
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Fisher Scientific) with 2 μl or 5 μl transfection reagent for 12 or 6 wells, respectively. The
siRNA sequences are listed in Table 4.
RNA analyses
The transcriptome analysis of TetR and TetR-IE1 cells using Affymetrix Human Gene 1.0 ST
Arrays has been described [21], and the complete set of data is accessible through Gene Expres-
sion Omnibus (National Center for Biotechnology Information), Series GSE24434 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE24434). To determine steady-state mRNA
levels by RT-qPCR, total RNA was isolated from fibroblasts cultured in 12-well dishes using
the RNeasy Mini Kit and RNase-Free DNase Set (Qiagen) according to the manufacturer’s pro-
tocols. First-strand cDNA was synthesized at 50°C using the AffinityScript Multiple Tempera-
ture cDNA Synthesis Kit and oligo(dT) primers (Agilent Technologies) starting with equal
amounts of total RNA. First-strand cDNA was diluted 10-fold in sterile ultrapure water, and
5 μl were used for real-time PCR exactly as described in detail in previous publications [21, 30].
The sequences of oligonucleotide primers used for qPCR are listed in Table 3.
Protein analyses
Preparation of whole cell protein extracts, sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis and immunoblotting were performed according to previously published proto-
cols [53, 93]. Subcellular fractionation was done as described [21]. For indirect immunofluores-
cence microscopy, cells were seeded on high-precision cover glasses with thickness No. 1.5H
(VWR, MARI 0117640) and processed as described [21]. Following immunostaining, samples
were covered with ProLong Gold Antifade Mountant with DAPI (Molecular Probes, P36931),
and deconvoluted images were acquired using a BZ-9000 Biorevo all-in-one fluorescence
microscope (Keyence).
For SUMOylation analysis, about 7×106 cells were lysed on ice in 500 μl buffer containing
50 mM Tris-HCl pH 7.5, 150 mMNaCl, 2 mMMgCl2, 0.5% (v/v) Igepal CA-630, 1% (v/v) Tri-
ton X-100, 1% (v/v) protease inhibitor cocktail III (Calbiochem), 1% (v/v) phosphatase inhibi-
tor cocktail II (Calbiochem) and 5 μg/ml N-ethylmaleimide. After sonification in a Branson
Sonifier 450 cup horn resonator (25 pulses at duty cycle 80% and output control 10), lysates
were cleared by centrifugation (20,000×g, 25 min, 4°C) and incubation with 20 μl mouse IgG
agarose (Sigma-Aldrich). Soluble material was reacted with 10 μl anti-HA agarose (Sigma-
Aldrich) for 2 h at 4°C with gentle rotation. Immune complexes were washed three times in
Table 4. siRNAs used in this study.
# Name Sequence (5‘!3‘)1 Company (catalog no.) Use
143 siSTAT3_1 UCUAGGUCAAUCUUGAGGCdCdT Ambion (s743) STAT3 knock-down
151 siSTAT3_2 AAUCUUAGCAGGAAGGUG CdCdT Ambion (s745) STAT3 knock-down
165 siJAK1_1 UUGUCAUCAACGGUGAUGGdTdG Ambion (s7646) JAK1 knock-down
166 siJAK1_2 UCCAUGAUGAGCUUAAUACdCdA Ambion (s7647) JAK1 knock-down
169 siIFNGR1_1 UACGAGUUUAAAGCGAUGCdTdG Ambion (s7193) IFNGR1 knock-down
170 siIFNGR1_2 UCAAUUGUAACAUUAGUUGdGdT Ambion (s7194) IFNGR1 knock-down
173 siIL6ST_1 UAAGAUACUAGACAGUUCCd TdC Ambion (s7317) IL6ST knock-down
174 siIL6ST_2 UAAUCAACAGUGCAUGAGGdTdG Ambion (s7318) IL6ST knock-down
149 siControl2 unknown 21-mer Ambion (4390843) non-targeting control
1 guide (antisense) strand; d, desoxy.
2 Silencer Select Negative Control No. 1 siRNA.
doi:10.1371/journal.ppat.1005748.t004
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modified radioimmunoprecipitation (RIPA) buffer (50 mM Tris-HCl pH 8.0, 150 mMNaCl,
0.1% [w/v] SDS, 1% [v/v] Igepal CA-630, 0.5% [w/v] sodium deoxycholate) and once in nucle-
ase reaction buffer (50 mM Tris-HCl pH 8.0, 2 mMMgCl2) before incubation with 25 U Ben-
zonase nuclease (Novagen) in a volume of 100 μl for 30 min. After two additional washing
steps in RIPA buffer, proteins were eluted by addition of 80 μl 1× sample buffer [124] and incu-
bation for 10 min at 95°C.
For co-immunoprecipitation analyses involving dox-treated TetR-IE1 fibroblasts, resting
cells of two 15-cm dishes were cross-linked by treatment with 1% (v/v) formaldehyde for 10
min at room temperature. Monolayers were washed twice in ice-cold serum-free DMEM, and
cells were scraped in DMEM supplemented with 1% protease inhibitor cocktail III, pelleted by
centrifugation (1,200×g, 10 min, 4°C) and lysed in 1.5 ml RIPA buffer supplemented with 1%
protease inhibitor cocktail III. After sonification (30 pulses at duty cycle 80% and output con-
trol 10 in a Branson Sonifier 450 cup horn resonator), lysates were cleared by centrifugation
(20,000×g, 30 min, 4°C). Supernatants were incubated with 150 μl Protein A Agarose/Salmon
Sperm DNA slurry (Millipore) for 45 min at 4°C. After centrifugation (14,000×g, 10 min, 4°C),
700 μl supernatant were incubated with 10 μg IE1/IE2 8B1.2 antibody or normal mouse IgG
for 16 h at 4°C with gentle rotation. Antigen-antibody complexes were isolated by addition of
60 μl Protein A Agarose/Salmon Sperm DNA slurry. Complexes were washed once in RIPA
buffer, and nucleic acids were removed by incubation with 25 U Benzonase nuclease in 100 μl
nuclease reaction buffer for 30 min at 4°C. After five additional washing steps in RIPA buffer,
bound proteins were eluted by incubation in 45 μl 1× sample buffer for 10 min at 99°C.
For co-immunoprecipitations involving plasmid-transfected 293T cell cultures, cells of a
10-cm dish were harvested in PBS without prior formaldehyde cross-linking. Cells were pel-
leted by centrifugation (550×g, 8 min, 4°C) and resuspended in 0.5 ml CoIP lysis buffer (50
mM Tris-HCl pH 8.0, 150 mMNaCl, 10% (v/v) glycerol, 0.5% (v/v) Triton X-100) supple-
mented with 1% protease inhibitor cocktail III. Lysates were incubated on ice for 10 min and
cleared by centrifugation (20,000×g, 30 min, 4°C). Supernatants were incubated with 25 μl
Pierce Anti-HAMagnetic Beads (ThermoFisher Scientific, 88836) for 2 h at 4°C with gentle
rotation. Complexes were washed five times in CoIP wash buffer (50 mM Tris-HCl pH 8.0, 150
mMNaCl, 0.1% (v/v) Igepal CA-630) and eluted by incubation in 50 μl 1× sample buffer for 5
min at 95°C.
ChIP coupled to qPCR was performed essentially as described [21, 30] with minor modifica-
tions. Briefly, cells were cross-linked for 15 min at 37°C. Sheared chromatin was centrifuged for
30 min to remove insoluble material, and the supernatant from 7×106 cells was subjected to a
pre-clearing step with 75 μl Protein A Agarose/Salmon Sperm DNA slurry for 30 min at 4°C
with gentle rotation. Immunoprecipitations were carried out using 10 μg STAT3 C-20 antibody
or normal rabbit IgG. Oligonucleotide primers used for subsequent qPCRs are listed in Table 3.
Bioinformatic analysis
The Core Analysis function (default analysis settings) of the Ingenuity Pathway Analysis soft-
ware application (Content version 24718999, Build version 366632M; Qiagen) was used to
explore upstream regulators in the human transcriptome repressed by IE1 relative to an Affy-
metrix Human Gene 1.0 ST Array reference set. Only direct and indirect relationships where
‘confidence = Experimentally Observed’ were considered.
Supporting Information
S1 Data. Human genes significantly up- or down-regulated by IE1 in the TetR-IE1 cell
model. The listed probe sets are linked to average changes of1.5-fold (up-regulated probe
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sets) or-1.5-fold (down-regulated probe sets) at a significance level of 0.001 (confidence
interval, CI = 99.9%) in GeneChip analyses comparing dox-treated TetR-IE1 (TetR-IE1+) to
dox-treated TetR (TetR+) cells or TetR-IE1+ to solvent-treated TetR-IE1 (TetR-IE1-) cells 24 h
or 72 h post induction. Data were derived from three replicate GeneChips (#1-#3) and include
robust multi-array average (RMA)-normalized log2 signals (single and mean values) with stan-
dard deviation (STDEV) and 99.9% CI as well as log2 signal ratios and mean fold changes. The
lists were filtered for and do not include probe sets with average changes of1.5-fold (up-regu-
lated probe sets) or-1.5-fold (down-regulated probe sets) in analyses comparing TetR+ to
TetR- cells at the corresponding (24 h or 72 h) post induction time. Probe sets significantly up-
or down-regulated in both comparisons (TetR-IE1+ vs. TetR+ and TetR-IE1+ vs. TetR-IE1-
cells) at the same post infection time are bold-typed. The complete GeneChip data are accessi-
ble at Gene Expression Omnibus, Series GSE24434 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE24434).
(XLS)
S1 Fig. The majority of human genes down-regulated by IE1 are STAT3 target genes.
MRC-5 cells transduced to express inducible shRNAs targeting firefly luciferase (shLUC) or
human STAT3 (shSTAT3_1 and shSTAT3_2) were treated with dox for 72 h. Relative mRNA
levels were determined by RT-qPCR with primers specific for the indicated cellular genes.
Results were normalized to TUBB, and means and standard deviations of biological triplicates
are shown in comparison to shLUC cells (set to 1).
(EPS)
S2 Fig. Residues 405–491 within the IE1 C-terminal domain are sufficient for STAT3 bind-
ing. 293T cells were transfected with plasmids encoding mCherry-HA, mCherry-HA-IE1
(wild-type), or mCherry-HA-NLS-IE1dl1-404 fusion proteins. At 48 h post transfection, whole
cell extracts were prepared and subjected to immunoprecipitations with anti-HA magnetic
beads. Samples of lysates and immunoprecipitates (IPs) were analyzed by immunoblotting for
STAT3α and HA-tagged proteins.
(EPS)
S3 Fig. Down-regulation of genes responsive to STAT3, IL6 or/and OSM precedes up-regu-
lation of genes responsive to STAT1 or/and IFNγ by IE1.Maximum average expression
changes in genes1.5-fold down- or up-regulated by IE1 (based on S1 Data) and regulated by
STAT3, IL6 or/and OSM or STAT1 or/and IFNγ, respectively (based on Ingenuity Pathway
Analysis), are compared between 24 h and 72 h following the onset of IE1 expression.
(EPS)
S4 Fig. Knock-down of IFNGR1 only modestly affects IE1-mediated induction of IFNγ-
stimulated genes. TetR (w/o) or TetR-IE1 (IE1) cells were transfected with a control siRNA or
two different siRNAs specific for IFNGR1. From 48 h post siRNA transfection, cells were
treated with dox for 72 h. During the last 24 h of dox treatment, cells were treated with IFNγ or
solvent. Relative mRNA levels were determined by RT-qPCR for IFNGR1, IE1 and the STAT1
target genes CXCL9, CXCL10 and CXCL11. Results were normalized to TUBB, and means and
standard deviations of two biological and two technical replicates are shown in comparison to
control siRNA-transfected cells (set to 1).
(EPS)
S5 Fig. Characterization of recombinant TB40/E BACs. Restriction fragment length analysis
of pTB- (A) or pgTB-derived (C) wt, IE1dl410-420 and rvIE1dl410-420 BACs (two indepen-
dent clones each) after digestion of 1.2 μg DNA with EcoRI and separation in a 0.7% agarose-
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Tris-acetate-EDTA gel stained with ethidium bromide. 10 ng of pTB- (B) or pgTB-derived (D)
wt, IE1dl410-420 and rvIE1dl410-420 BACs were PCR-amplified using IE1-specific oligonu-
cleotide primers #151 and #927 (B) or #430 and #1165 (D), and PCR products were separated
in a 1.0% agarose-Tris-acetate-EDTA gel stained with ethidium bromide.
(EPS)
S6 Fig. Nuclear accumulation of STAT3 in hCMV-infected cells. (A) MRC-5 cells were
mock-infected or infected with TBwt, TBIE1dl410-420 or TBrvIE1dl410-420 at high input
multiplicity (5 PFU/cell). At 24 h post infection, subcellular localization of endogenous STAT3
was analyzed by indirect immunofluorescence microscopy. Samples were simultaneously
reacted with a rabbit polyclonal antibody to STAT3 and a mouse monoclonal antibody to IE1,
followed by incubation with a rabbit-specific Alexa Fluor 488 conjugate and a mouse-specific
Alexa Fluor 594 conjugate. Cell nuclei were visualized by DAPI staining. Additionally, merge
images of STAT3, IE1 and DAPI signals are presented. (B) Fluorescence intensities of STAT3
staining within the nucleus and cytoplasm were determined for 50 cells per each infection. The
mean nuclear-to-cytoplasmic ratios (N/C) and standard deviations of the mean are shown.
(EPS)
S7 Fig. IE1 rewires IL6 signaling to STAT1 activation also late in hCMV infection. (A)
MRC-5 cells were mock-infected or infected with TBwt, TBIE1dl410-420 or TBrvIE1dl410-420
at high input multiplicity (5 PFU/cell). At 6 h post infection, cultures were treated with solvent
or IL6 plus IL6R (IL6/Rα). At 72 h post infection, whole cell protein extracts were prepared
and analyzed by immunoblotting for IE1/IE2, total STAT1, pSTAT1 (Y701) and GAPDH. (B)
MRC-5 cells were mock-infected or infected with TBwt, TBIE1dl410-420 or TBrvIE1dl410-420
at high input multiplicity (5 PFU/cell). At 6 h post infection, cultures were treated with solvent
or IL6 plus IL6R (IL6/Rα). At 72 h post infection, relative mRNA levels were determined by
RT-qPCR for the STAT1 target gene CXCL9. Results were normalized to TUBB, and means
and standard deviations of biological triplicates are shown in comparison to solvent-treated
mock-infected cells (set to 1).
(EPS)
S8 Fig. STAT3 knock-down inhibits replication of gTBwt and gTBIE1dl410-420. (A) MRC-
5 cells transduced to express inducible shRNAs targeting firefly luciferase (shLUC) or human
STAT3 (shSTAT3) were treated with dox for 72 h and then infected with gTBwt or
gTBIE1dl410-420 at low input multiplicity (0.01 PFU/cell). Every 48 h, half of the culture
media was replaced, and viral replication was assessed at day 7 post infection by fluorescence
microscopy. (B) MRC-5 cells transduced to express inducible shRNAs targeting firefly lucifer-
ase (shLUC) or human STAT3 (shSTAT3) were treated with dox for 72 h and then infected
with gTBwt or gTBIE1dl410-420 at low input multiplicity (0.01 PFU/cell). Every 48 h, half of
the culture media was replaced, and viral replication was assessed at day 7 post infection by
qPCR-based relative quantification of hCMV DNA from culture supernatants with oligonucle-
otide primers specific for the viral UL86 sequence. Data are presented as means and standard
deviations from two biological and two technical replicates relative to gTBwt-infected shLuc
cells (set to 1).
(EPS)
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